SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2007 by Massachusetts General Hospital.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute
Information provided by:
Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00361244
First received: August 4, 2006
Last updated: December 28, 2007
Last verified: December 2007
  Purpose

The purpose of this study is to determine the safety of SU011248 and the highest dose of this drug that can be given safely in combination with the chemotherapy drugs irinotecan and cetuximab. Laboratory studies have shown that SU011248 may block the growth of blood vessels in tumors, which may prevent tumors from growing any further. Other studies have demonstrated the possibility that SU011248 may enhance the anti-tumor activity of other chemotherapy drugs such as irinotecan and cetuximab.


Condition Intervention Phase
Colorectal Carcinoma
Drug: SU011248
Drug: Irinotecan
Drug: Cetuximab
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Study of SU011248 (Sutent) in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Patients With Stage IV Colorectal Cancer

Resource links provided by NLM:


Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • To determine the maximum tolerated dose of SU011248 when given in combination with irinotecan and cetuximab in patients with previously treated locally advanced, locally recurrent, or metastatic colorectal adenocarcinoma [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • To determine the response rate of SU011248 when given in combination with irinotecan and cetuximab in this patient population. [ Time Frame: TBD ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To evaluate the toxicities of this combination of drugs in this patient population [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • to assess overall survival, progression-free survival, time to progression and duration of response. [ Time Frame: TBD ] [ Designated as safety issue: No ]

Estimated Enrollment: 44
Study Start Date: July 2006
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: SU011248
    Given orally in the morning for two weeks followed by a one week rest period (one cycle equals 21 days). Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
    Drug: Irinotecan
    Given intravenously on days 1 and 8 of each 21-day cycle. Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
    Drug: Cetuximab
    Given intravenously on days 8 and 15 of each 21-day cycle. Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
Detailed Description:
  • Participants will be given a supply of SU011248 capsules to take at home in the morning for two weeks. After taking the capsules for two weeks, there will be a one-week rest period.
  • Irinotecan will be administered on days 1 and 8 of every 21-day cycle as an intravenous infusion over 90 minutes. Cetuximab will be administered intravenously on days 1, 8 and 15 of every 21-day cycle. The first treatment of cetuximab is a larger dose. Beginning with the second treatment, the participant will receive a smaller dose of cetuximab.
  • Blood work will be repeated at every clinic visit on days 1 and 8. During cycle 1, blood will also be drawn on day 15.
  • Tumor assessments will be repeated after 6 weeks, 12 weeks, and every 9 weeks thereafter, and will be assessed by both a CT scan of the abdomen, pelvis, and a chest x-ray. MUGA scans will be repeated every 4 cycles (12 weeks).
  • Participants may continue to receive cycles of study treatment as long as their disease does not progress and they do not experience any serious side effects.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologic proof of adenocarcinoma of the colon or rectum with evidence of metastatic disease. The site of the primary lesion must be or have been confirmed endoscopically, radiologically, or surgically to be or have been in the large bowel
  • Patients must have received one (and only one) prior chemotherapy regimen for metastatic disease using 5-FU/LV or Xeloda in combination with oxaliplatin and Avastin.
  • > 4 weeks must have elapsed from the time of major surgery
  • > 2 weeks must have elapsed from the time of minor surgery
  • > 4 weeks must have elapsed from the time of major radiotherapy
  • Normal organ and marrow function
  • Measurable disease be RECIST criteria
  • Older than 18 years of age
  • ECOG performance status of 0-1
  • Life expectancy > 12 weeks

Exclusion Criteria:

  • Previous treatment with irinotecan, cetuximab or SU011248
  • Any of the following within the 12 months prior to study drug administration: severe/unstable angina; myocardial infarction; symptomatic congestive heart failure; cerebrovascular accident; or transient ischemic attack.
  • Known brain metastases or carcinomatous meningitis
  • Uncontrolled serious medical or psychiatric illness
  • NCI CTCAE grade 3 or greater hemorrhage within 4 weeks of starting study treatment
  • Uncontrolled hypertension
  • Diagnosis of any secondary malignancies with the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, localized prostate cancer with a normal PSA within the past 3 months, in situ bladder cancer, or in situ cervical cancer
  • Pregnant or breastfeeding
  • Concurrent treatment on another clinical trial
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00361244

Locations
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02115
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute
Investigators
Principal Investigator: Andrew X. Zhu, MD Massachusetts General Hospital
  More Information

No publications provided

Responsible Party: Andrew Zhu, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00361244     History of Changes
Other Study ID Numbers: 05-439
Study First Received: August 4, 2006
Last Updated: December 28, 2007
Health Authority: United States: Food and Drug Administration

Keywords provided by Massachusetts General Hospital:
Sutent

Additional relevant MeSH terms:
Carcinoma
Colorectal Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Irinotecan
Cetuximab
Sunitinib
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Radiation-Sensitizing Agents
Physiological Effects of Drugs
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances

ClinicalTrials.gov processed this record on April 16, 2014